title: [Adult T cell leukemia/lymphoma (ATL)].
abstract: Adult T cell leukemia/lymphoma(ATL) is an aggressive, fatal malignancy associated with human T-lymphotropic virus type I(HTLV-I). The median survival time of acute- and lymphoma-type ATL is 6 and 10 months, respectively. According to recent reports, nearly half of the ATL patients who received allogeneic hematopoietic stem cell transplantation could survive without disease for over 3 years. However, the population of patients who are eligible for conventional transplantation is extremely limited. Therefore, a reduced-intensity allogeneic stem cell transplantation(RIST) is applied to ATL patients and a multi-center phase I clinical trial is now underway. In our institute, 5 patients, who received RIST, are all alive, with 1 case relapsed after 6 months. Thus, RIST is considered very promising.
mesh_terms: D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D019172:Transplantation Conditioning / Q000379:methods; D014184:Transplantation, Homologous